Desmoid Tumors Market Report 2026

The desmoid tumors market size has grown strongly in recent years. It will grow from $3.15 billion in 2025 to $3.35 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to limited awareness of rare tumors, reliance on surgery, lack of targeted drugs, hospital-based oncology care, delayed diagnosis.

The desmoid tumors market size is expected to see strong growth in the next few years. It will grow to $4.42 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to advancements in molecular therapies, growth of rare disease pipelines, increasing clinical trials, improved diagnostic imaging, expanding specialty centers. Major trends in the forecast period include shift toward non-surgical management, rising use of targeted molecular therapies, growth of watchful waiting strategies, expansion of multidisciplinary care models, increased focus on rare disease research.

The increasing incidence of cancer is expected to drive the growth of the desmoid tumor market in the coming years. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. These cells can invade surrounding tissues and organs, leading to significant health complications. The rising number of cancer cases globally has increased the demand for effective and advanced chemotherapeutic agents, which has positively influenced the desmoid tumor market. For instance, in October 2025, according to the National Health Service (NHS), a UK-based government health authority, there were 354,820 new cancer diagnoses recorded in 2023, averaging 972 cases per day, which was 8,605 more than in 2022. Therefore, the growing number of cancer cases is contributing to the expansion of the desmoid tumor market.

Major companies operating in the desmoid tumors market are increasingly focusing on the development of innovative drugs, such as nirogacestat, to address the treatment needs of patients more effectively. Nirogacestat is an oral, small-molecule gamma-secretase inhibitor designed for the treatment of desmoid tumors. For instance, in February 2023, SpringWorks Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had accepted and granted priority review to its new drug application (NDA) for nirogacestat for the treatment of adults with desmoid tumors. Nirogacestat is believed to function by inhibiting the production of notch proteins, which can result in tumor cell death. Desmoid tumors are known to produce elevated levels of notch protein, which is thought to support tumor growth. Additionally, nirogacestat offers patients a new therapeutic option that may help improve treatment outcomes.

In January 2023, Advaxis Inc., a US-based biotechnology company, completed a merger with Ayala Pharmaceuticals Inc. This merger was aimed at forming a combined organization focused on the development and commercialization of Ayala’s lead candidate, AL102, for the treatment of desmoid tumors. The transaction is intended to accelerate the clinical development and commercialization of AL102 while strengthening and diversifying the overall oncology portfolio. Ayala Pharmaceuticals Inc. is a US-based biotechnology company engaged in the development of AL102, a vaccine candidate intended for the treatment of desmoid tumors.

Major companies operating in the desmoid tumors market are Pfizer Inc., F.Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Amgen Inc., Eisai Limited, Incyte Corporation, Ipsen Biopharmaceuticals Inc., BeiGene Ltd., Janssen Biotech Inc., Blueprint Medicines Corporation, Debiopharm Group, Clovis Oncology Inc., SpringWorks Therapeutics Inc., Loxo Oncology Inc., Mirati Therapeutics Inc., Iterion Therapeutics Inc., Recepta Pharmaceuticals Inc., Cellestia Biotech AG.

North America was the largest region in the desmoid tumors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the desmoid tumors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the desmoid tumors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the desmoid tumors market by increasing costs of imported targeted therapies, diagnostic equipment, and oncology drugs. Specialty centers in North America and Europe are most affected due to reliance on imported treatments, while Asia-Pacific faces higher access costs. These tariffs are increasing care expenses. However, they are encouraging domestic oncology research and drug development.

The desmoid tumors market research report is one of a series of new reports that provides desmoid tumors market statistics, including desmoid tumors industry global market size, regional shares, competitors with a desmoid tumors market share, detailed desmoid tumors market segments, market trends and opportunities, and any further data you may need to thrive in the desmoid tumors industry. This desmoid tumors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Desmoid tumors are rare, non-cancerous benign growths that originate from connective tissue cells, most commonly in the fascia, the tissue that surrounds muscles, nerves, and blood vessels. These tumors are considered locally aggressive, meaning they can grow and infiltrate nearby tissues but do not metastasize or spread to distant areas of the body like malignant cancers.

The primary treatment options for desmoid tumors include surgery, radiation therapy, anti-inflammatory medications, hormone therapy, chemotherapy, novel molecular-targeted therapies, and others. Surgery involves medical procedures performed to remove or repair tissues or organs within the body. Diagnosis is carried out using methods such as biopsy, electron microscopic examination, immunohistochemical analysis, and other techniques, with care provided by hospitals, clinics, specialty centers, and others.

The desmoid tumors market consists of revenues earned by entities by providing services such as gleevec-based therapy, sorafenib-based therapy, long-term monitoring, resonance imaging (MRI), computed tomography (CT) scans, ultrasound, and fine needle aspiration techniques (FNA) that aid in the diagnosis of desmoid tumors. The market value includes the value of related goods sold by the service provider or included within the service offering. The desmoid tumors market also includes sales of surgical tools, linear accelerators, immunotherapy drugs, and anti-fibrotic agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.